MarketCap
Facebook
X
TelegramAnnual report 2025
added 02-24-2026
PerkinElmer General and Administrative Expenses 2011-2026 | PKI
General and Administrative Expenses — these are a part of a company's operating expenses that are not directly related to the production of goods or the provision of services but are necessary for the overall functioning of the business.What these expenses include
- Salaries of administrative staff (executives, HR, accountants, legal personnel)
- Office rent and utilities
- Office equipment and IT infrastructure
- Professional services (auditors, lawyers, consultants)
- Insurance
- General administrative travel and representation expenses
- Cost control
A high level of such expenses may indicate inefficient management or an overly complex structure - Profitability
Reducing administrative expenses while maintaining stable revenue increases operating profit - Comparative analysis
Investors can compare this metric as a percentage of revenue among companies in the same industry - Business flexibility
Companies with a flexible and controlled expense structure are more resilient to revenue declines
Annual General and Administrative Expenses PerkinElmer
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 992 M | 994 M | 1.02 B | 975 M | 716 M | - | 809 M | 812 M | 590 M | 587 M | - | 659 M | 586 M | 627 M | 474 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 1.02 B | 474 M | 757 M |
Quarterly General and Administrative Expenses PerkinElmer
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 242 M | 249 M | 250 M | - | 238 M | 252 M | 261 M | - | 250 M | 267 M | 249 M | - | 243 M | 263 M | 275 M | - | 276 M | 282 M | 251 M | - | 225 M | 221 M | 209 M | - | 204 M | 202 M | 199 M | - | 197 M | 205 M | 200 M | - | 153 M | 150 M | 147 M | - | 143 M | 151 M | 145 M | - | 148 M | 147 M | 146 M | - | 143 M | 147 M | 152 M | - | 143 M | 148 M | 151 M | - | 145 M | 150 M | 157 M | - | 133 M | 138 M | 133 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 282 M | 133 M | 195 M |
General and Administrative Expenses of other stocks in the Diagnostics research industry
| Issuer | General and Administrative Expenses | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Centogene N.V.
CNTG
|
46.7 M | - | -6.23 % | $ 30.6 M |  Germany |
 |
Agilent Technologies
A
|
1.62 B | $ 114.78 | -0.61 % | $ 34.9 B |  USA |
|
Biodesix
BDSX
|
80.5 M | $ 15.7 | 4.18 % | $ 2.04 B | USA |
 |
Biomerica
BMRA
|
2.98 M | $ 2.15 | -0.83 % | $ 4.94 M | USA |
 |
BioNano Genomics
BNGO
|
35.2 M | $ 1.16 | -3.33 % | $ 6.32 M | USA |
 |
Burning Rock Biotech Limited
BNR
|
490 M | $ 16.33 | 0.8 % | $ 176 M |  China |
 |
CareDx, Inc
CDNA
|
108 M | $ 18.12 | -1.04 % | $ 966 M | USA |
 |
Celcuity
CELC
|
27.2 M | $ 114.33 | 1.5 % | $ 5.35 B | USA |
 |
Aspira Women's Health
AWH
|
7.96 M | - | -6.19 % | $ 10.5 M | USA |
 |
Biocept
BIOC
|
16.1 M | - | -13.05 % | $ 7.29 M | USA |
 |
Co-Diagnostics
CODX
|
9.06 M | $ 4.4 | 101.83 % | $ 5.85 M | USA |
 |
Charles River Laboratories International
CRL
|
743 M | $ 166.88 | -4.03 % | $ 8.27 B | USA |
 |
Castle Biosciences
CSTL
|
200 M | $ 25.0 | 0.64 % | $ 694 M | USA |
 |
Check-Cap Ltd.
CHEK
|
9.46 M | - | - | $ 9.42 M |  Israel |
 |
Danaher Corporation
DHR
|
8.24 B | $ 191.23 | 0.06 % | $ 136 B | USA |
 |
DexCom
DXCM
|
1.29 B | $ 63.01 | 1.26 % | $ 24.6 B | USA |
 |
Oxford Immunotec Global PLC
OXFD
|
22.3 M | - | - | $ 562 M |  Britain |
|
Akumin
AKU
|
2.08 M | - | -17.87 % | $ 25.9 M |  Canada |
 |
Fulgent Genetics
FLGT
|
88.1 M | $ 16.56 | -1.55 % | $ 501 M | USA |
 |
Guardant Health
GH
|
211 M | $ 90.84 | -3.19 % | $ 11.4 B | USA |
 |
Accelerate Diagnostics
AXDX
|
39.2 M | - | -61.36 % | $ 2.46 M | USA |
 |
ICON Public Limited Company
ICLR
|
585 M | $ 111.1 | -2.71 % | $ 9.16 B |  Irlanda |
 |
Interpace Biosciences
IDXG
|
9.48 M | $ 1.92 | -1.92 % | $ 8.49 M | USA |
 |
Illumina
ILMN
|
1.09 B | $ 126.95 | -0.34 % | $ 20.2 B | USA |
 |
Global Cord Blood Corporation
CO
|
187 M | - | - | $ 399 M | China |
 |
IQVIA Holdings
IQV
|
2 B | $ 169.58 | -2.12 % | $ 29.2 B | USA |
 |
Fluidigm Corporation
FLDM
|
97.9 M | - | 1.08 % | $ 308 M | USA |
 |
Genetic Technologies Limited
GENE
|
3.83 M | - | - | $ 7.1 B |  Australia |
 |
Genetron Holdings Limited
GTH
|
126 M | - | 0.12 % | $ 80.1 M | China |
 |
Exact Sciences Corporation
EXAS
|
889 M | - | - | $ 19.8 B | USA |
 |
PRA Health Sciences, Inc.
PRAH
|
453 M | - | - | $ 10.7 B | USA |
 |
Laboratory Corporation of America Holdings
LH
|
2.22 B | $ 274.35 | 0.23 % | $ 22.8 B | USA |
 |
Lantheus Holdings
LNTH
|
275 M | $ 75.67 | -0.57 % | $ 5.11 B | USA |
 |
DermTech
DMTK
|
43.8 M | - | -11.32 % | $ 2.94 M | USA |
 |
Medpace Holdings
MEDP
|
198 M | $ 494.14 | -0.84 % | $ 14.3 B | USA |
 |
Mettler-Toledo International
MTD
|
998 M | $ 1 256.28 | -0.29 % | $ 25.9 B |  Schweiz |
 |
Myriad Genetics
MYGN
|
257 M | $ 4.76 | 0.11 % | $ 441 M | USA |
 |
Enzo Biochem
ENZ
|
21.7 M | - | -8.98 % | $ 14.8 K | USA |
 |
ENDRA Life Sciences
NDRA
|
3.72 M | $ 4.57 | -2.46 % | $ 3.6 M | USA |
 |
NeoGenomics
NEO
|
273 M | $ 7.98 | -0.25 % | $ 1.02 B | USA |
 |
Neogen Corporation
NEOG
|
218 M | $ 9.51 | 1.01 % | $ 2.06 B | USA |
 |
National Research Corporation
NRC
|
54.8 M | $ 17.43 | 1.6 % | $ 390 M | USA |
 |
Natera
NTRA
|
589 M | $ 204.77 | -1.54 % | $ 20.2 B | USA |
 |
Pacific Biosciences of California
PACB
|
141 M | $ 1.41 | 5.05 % | $ 423 M | USA |
 |
Koninklijke Philips N.V.
PHG
|
599 M | $ 27.02 | -0.33 % | $ 20 B |  Niderland |
 |
Precipio
PRPO
|
9.45 M | $ 26.84 | 5.67 % | $ 43.1 M | USA |
 |
Personalis
PSNL
|
46.2 M | $ 6.64 | 0.84 % | $ 393 M | USA |
 |
RadNet
RDNT
|
1.82 M | $ 55.13 | 0.62 % | $ 4.15 B | USA |
 |
Heska Corporation
HSKA
|
64.1 M | - | - | $ 1.31 B | USA |
 |
HTG Molecular Diagnostics
HTGM
|
15.8 M | - | -20.0 % | $ 1.06 M | USA |